Background Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there are few data on work and household productivity among pts with PsA.2 RAPID-PsA (NCT01087788) reports the efficacy and safety of certolizumab pegol (CZP) in pts with moderate to severe PsA.3
Objectives To estimate the economic burden of moderate to severe PsA in terms of workplace and household productivity using data from RAPID-PsA.
Methods The ongoing 158-week (wk) RAPID-PsA trial recruited pts with active PsA. The impact of PsA on workplace and household productivity and daily activities was assessed at study baseline (BL), using the arthritis-specific Work Productivity Survey (WPS).4
Results At BL, pts had a mean age of 48 years and 55% were female; 61.6% had psoriasis skin involvement ≥3% body surface area (BSA). 59.4% of pts were employed outside the home, 13.9% were work disabled due to PsA and 13.5% were retired. Overall, a high burden of PsA on workplace and household productivity was reported, with on average >1 wk of paid work affected and >2 wks of household duties or social activities affected per month (Table). Household productivity losses were, on average, up to 2 to 3 times higher in non-employed or disease work disabled pts vs employed pts: on average household duties were affected 18 days or 26 days vs 11 days/month (Table). Employed PsA pts with manual jobs reported higher productivity losses at work and within home vs employed pts with non-manual jobs (Table). Overall 41.8% of pts required regular assistance from relatives, friends or paid caregivers in their usual activities because of PsA. These pts reported on average 2 to 4 times higher workplace and household productivity losses vs pts who did not require help (Table).
Conclusions PsA is associated with a high burden of disease on workplace and household productivity that could lead to large financial burden for pts and society. Effective PsA treatments are needed to prevent disability and work losses, and reduce economic burden of the disease.
Mau W. J Rheumatol 2005;32:721-728;
Tillet W. Rheumatology 2012;51:275-283;
Mease P. Ann Rheum Dis 2012;71(Suppl3):150;
Osterhaus J. Arth Res Ther 2009;11(3):R73
Acknowledgements The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma.
Disclosure of Interest A. Kavanaugh Grant/research support from: Abbott, Amgen, BMS, Pfizer, Roche, Janssen, UCB Pharma, P. Mease Grant/research support from: Abbott, Amgen, BiogenIdec, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Consultant for: Abbott, Amgen, BiogenIdec, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, O. Purcaru Employee of: UCB Pharma, D. van der Heijde Grant/research support from: AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Daiichi, Eli Lilly, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, Vertex, Consultant for: AbbVie, Amgen, AstraZeneca, BMS, Centocor, Chugai, Daiichi, Eli Lilly, GSK, Janssen, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma, Vertex, Employee of: Imaging Rheumatology bv.